PTJ
ALNY icon

Paul Tudor Jones’s Alnylam Pharmaceuticals ALNY Stock Holding History

Paul Tudor Jones’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$361K Buy
1,200
+300
+33% +$90.5K ﹤0.01% 3013
2026
Q1 		$298K Sell
900
-1,800
-67% -$613K ﹤0.01% 3142
2025
Q4 		$1.07M Sell
2,700
-300
-10% -$133K ﹤0.01% 2222
2025
Q3 		$1.37M Buy
3,000
+2,000
+200% +$814K ﹤0.01% 2053
2025
Q2 		$326K Hold
1,000
– – ﹤0.01% 2841
2025
Q1 		$270K Sell
1,000
-3,500
-78% -$899K ﹤0.01% 2665
2024
Q4 		$1.06M Sell
4,500
-2,600
-37% -$684K ﹤0.01% 1689
2024
Q3 		$1.95M Buy
+7,100
New +$1.85M 0.01% 1215

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's ALNY Position: Q4 2024 in Review

Paul Tudor Jones sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 3,386 shares — an estimated $890K sold.

Paul Tudor Jones first reported a position in ALNY in Q4 2014 and held it in 14 quarters. The position peaked at $14.7M in Q2 2024. 594 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

  • Paul Tudor Jones reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Paul Tudor Jones sold 3,386 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $890K.
  • Paul Tudor Jones first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 14 quarters.
  • Paul Tudor Jones's Alnylam Pharmaceuticals position peaked at $14.7M in Q2 2024.
  • 594 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Tudor Investment Corp's 13F filing for Q4 2024, filed 14 Feb 2025.